Pharmarise Holdings Corp. (2796) Stock Statistics & Valuation Metrics

Pharmarise Holdings Corp. has a market cap or net worth of ¥5.96B. The enterprise value is ¥14.93B.

Pharmarise Holdings Corp. has 12,060,381 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pharmarise Holdings Corp.’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -61.72%.

The current PE Ratio of Pharmarise Holdings Corp. is ―. Pharmarise Holdings Corp.’s PEG ratio is ―.

In the last 12 months, Pharmarise Holdings Corp. had revenue of 63.51B and earned -367.00M in profits. Earnings per share was -32.42.

In the last 12 months, operating cash flow was 427.00M and capital expenditures -77.50M, giving a free cash flow of 349.50M billion.

Pharmarise Holdings Corp. pays an annual dividend of ¥14, resulting in a dividend yield of 2.77%

Pharmarise Holdings Corp. upcoming earnings date is Sep 25, 2025, TBA (Confirmed).

Pharmarise Holdings Corp. as a current ratio of 1.10, with Debt / Equity ratio of 207.94%

In the past 12 months, Pharmarise Holdings Corp. has paid 391.00M in taxes.

Pharmarise Holdings Corp. EV to EBITDA ratio is 8.85, with an EV/FCF ratio of 24.40.

Pharmarise Holdings Corp. has ¥2.24B in cash and marketable securities with ¥14.25B in debt, giving a net cash position of ¥12.00B billion.

Gross margin is 13.49%, with operating margin of 0.46%, and net profit margin of -0.58%.

The average price target for Pharmarise Holdings Corp. is ¥520.00, which is 11.43% higher than the current price. The consensus rating is Hold